IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Addiction is a chronic relapsing disease with high morbidity and mortality. Treatments for addiction include pharmacological and psychosocial interventions; however, currently available medications are limited in number and efficacy. The glucagon-like-peptide-1 (GLP-1) system is emerging as a potential novel pharmacotherapeutic target for alcohol and other substance use disorders (ASUDs). In this review, we summarize and discuss the wealth of available evidence from testing GLP-1 receptor (GLP-1R) agonist medications in preclinical models and humans with ASUDs, possible mechanisms underlying the impact of GLP-1R agonists on alcohol/substance use, gaps in knowledge, and future directions. Most of the research with GLP-1R agonists has been conducted in relation to alcohol use; psychostimulants, opioids, and nicotine have also been investigated. Preclinical evidence suggests that GLP-1R agonists reduce alcohol/substance use and other related outcomes. The main proposed mechanisms are related to reward processing, stress, and cognitive function, as well as broader mechanisms related to satiety, changes in gastric motility, and glucose homeostasis. More in-depth mechanistic studies are warranted. Clinical studies have been limited and their findings have been less conclusive; however, most support the safety and potential efficacy of GLP-1R agonists in ASUD treatment. Identifying preferred compounds, as well as possible subgroups who are most responsive to GLP-1R agonists are some of the key research questions to translate the promising preclinical data into clinical settings. Several clinical trials are underway to test GLP-1R agonists in people with ASUDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neurobiology of addiction: a neurocircuitry analysis
Koob, G. F., & Volkow, N. D. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)00104-8 · Cited by 3,698
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Neurobiologic advances from the brain disease model of addiction
Volkow, N. D., Koob, G. F., & McLellan, A. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1511480 · Cited by 2,008
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Addiction Is a Brain Disease, and It Matters
Leshner, A. I. (1997) · Science · doi:10.1126/science.278.5335.45 · Cited by 1,615
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Interactions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Gejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development
Koob, G. F. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000083 · Cited by 337
Kanoski, S. E., Rupprecht, L. E., Fortin, S. M., De Jonghe, B. C., & Hayes, M. R. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.12.022 · Cited by 273
Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A.-M. Ø., Zeeman, V. A., Johannsen, C.-F., Lee, A., Thomsen, G. K., Macoveanu, J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159863 · Cited by 262
The role of glucagon‐like peptide 1 (GLP‐1) in addictive disorders
Klausen, M. K., Thomsen, M., Wortwein, G., & Fink‐Jensen, A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15677 · Cited by 259
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
Self-citationThe glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
Egecioglu, E., Steensland, P., Fredriksson, I., Feltmann, K., Engel, J. A., & Jerlhag, E. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.11.009 · Cited by 207
Wharton, S., Calanna, S., Davies, M., Dicker, D., Goldman, B., Lingvay, I., Mosenzon, O., Rubino, D. M., Thomsen, M., Wadden, T. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14551 · Cited by 200
GLP-1 acts on habenular avoidance circuits to control nicotine intake
Tuesta, L. M., Chen, Z., Duncan, A., Fowler, C. D., Ishikawa, M., Lee, B. R., Liu, X.-A., Lu, Q., Cameron, M., Hayes, M. R., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4540 · Cited by 200
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
State-Level Economic Costs of Opioid Use Disorder and Fatal Opioid Overdose — United States, 2017
Luo, F., Li, M., & Florence, C. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7015a1 · Cited by 166
Operant alcohol self-administration in dependent rats: Focus on the vapor model
Vendruscolo, L. F., & Roberts, A. J. (2014) · Alcohol · doi:10.1016/j.alcohol.2013.08.006 · Cited by 166
Self-citationSemaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Aranäs, C., Edvardsson, C. E., Shevchouk, O. T., Zhang, Q., Witley, S., Blid Sköldheden, S., Zentveld, L., Vallöf, D., Tufvesson-Alm, M., & Jerlhag, E. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104642 · Cited by 158
Egecioglu, E., Engel, J. A., & Jerlhag, E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077284 · Cited by 158
Schmidt, H. D., Mietlicki-Baase, E. G., Ige, K. Y., Maurer, J. J., Reiner, D. J., Zimmer, D. J., Van Nest, D. S., Guercio, L. A., Wimmer, M. E., Olivos, D. R., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.362 · Cited by 148
Suchankova, P., Yan, J., Schwandt, M. L., Stangl, B. L., Caparelli, E. C., Momenan, R., Jerlhag, E., Engel, J. A., Hodgkinson, C. A., Egli, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.68 · Cited by 146
Self-citationJensen, C. B., Pyke, C., Rasch, M. G., Dahl, A. B., Knudsen, L. B., & Secher, A. (2018) · Endocrinology · doi:10.1210/en.2017-00812 · Cited by 145
Vadini, F., Simeone, P. G., Boccatonda, A., Guagnano, M. T., Liani, R., Tripaldi, R., Di Castelnuovo, A., Cipollone, F., Consoli, A., & Santilli, F. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0535-5 · Cited by 110
Reddy, I. A., Pino, J. A., Weikop, P., Osses, N., Sørensen, G., Bering, T., Valle, C., Bluett, R. J., Erreger, K., Wortwein, G., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.86 · Cited by 96
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118645 · Cited by 96
Effects of dulaglutide on alcohol consumption during smoking cessation
Probst, L., Monnerat, S., Vogt, D. R., Lengsfeld, S., Burkard, T., Meienberg, A., Bathelt, C., Christ-Crain, M., & Winzeler, B. (2023) · JCI Insight · doi:10.1172/jci.insight.170419 · Cited by 94
Medications for substance use disorders
Douaihy, A. B., Kelly, T. M., & Sullivan, C. (2013) · Social Work in Public Health · doi:10.1080/19371918.2013.759031 · Cited by 93
Wium‐Andersen, I. K., Wium‐Andersen, M. K., Fink‐Jensen, A., Rungby, J., Jørgensen, M. B., & Osler, M. (2022) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13776 · Cited by 93
Zhang, Y., Kahng, M. W., Elkind, J. A., Weir, V. R., Hernandez, N. S., Stein, L. M., & Schmidt, H. D. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0531-4 · Cited by 92
Dong, M., Wen, S., & Zhou, L. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s375559 · Cited by 90
Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
Rhea, E. M., Babin, A., Thomas, P., Omer, M., Weaver, R., Hansen, K., Banks, W. A., & Talbot, K. (2024) · Tissue Barriers · doi:10.1080/21688370.2023.2292461 · Cited by 81
Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1063033 · Cited by 80
Li, Q., Jia, M., Yan, Z., Li, Q., Sun, F., He, C., Li, Y., Zhou, X., Zhang, H., Liu, X., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020734 · Cited by 77
Angarita, G. A., Matuskey, D., Pittman, B., Costeines, J. L., Potenza, M. N., Jastreboff, A. M., Schmidt, H. D., & Malison, R. T. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108614 · Cited by 75
Bornebusch, A. B., Fink-Jensen, A., Wörtwein, G., Seeley, R. J., & Thomsen, M. (2019) · eneuro · doi:10.1523/eneuro.0443-18.2019 · Cited by 72
Richards, J. R., Dorand, M. F., Royal, K., Mnajjed, L., Paszkowiak, M., & Simmons, W. K. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.23m15068 · Cited by 59
Douton, J. E., Horvath, N., Mills‐Huffnagle, S., Nyland, J. E., Hajnal, A., & Grigson, P. S. (2022) · Addiction Biology · doi:10.1111/adb.13117 · Cited by 54
Ghidewon, M., Wald, H. S., McKnight, A. D., De Jonghe, B. C., Breen, D. M., Alhadeff, A. L., Borner, T., & Grill, H. J. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14663 · Cited by 51
Farokhnia, M., Browning, B. D., Crozier, M. E., Sun, H., Akhlaghi, F., & Leggio, L. (2022) · Addiction Biology · doi:10.1111/adb.13211 · Cited by 46
Self-citationLüthi, H., Lengsfeld, S., Burkard, T., Meienberg, A., Jeanloz, N., Vukajlovic, T., Bologna, K., Steinmetz, M., Bathelt, C., Sailer, C. O., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102429 · Cited by 42
Alcohol and Alcohol-related Diseases
(2023) · doi:10.1007/978-3-031-32483-3 · Cited by 38
Farokhnia, M., Fede, S. J., Grodin, E. N., Browning, B. D., Crozier, M. E., Schwandt, M. L., Hodgkinson, C. A., Momenan, R., & Leggio, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-17190-3 · Cited by 32
Self-citationZhu, C., Li, H., Kong, X., Wang, Y., Sun, T., & Wang, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.819470 · Cited by 26
Aranäs, C., Blid Sköldheden, S., & Jerlhag, E. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1180512 · Cited by 20
Research works printed but not linked: 77
- Connery, 2020, Substance use disorders in global mental health delivery: epidemiology, treatment gap, and implementation of evidence-based treatments, Harv. Rev. Psychiatry, 28, 316, 10.1097/HRP.0000000000000271 · DOI
- Carroll, 2021, The profound heterogeneity of substance use disorders: Implications for treatment development, Curr. Dir. Psychol. Sci., 30, 358, 10.1177/09637214211026984 · DOI
- Witkiewitz, 2019, Advances in the science and treatment of alcohol use disorder, Sci. Adv., 5, 10.1126/sciadv.aax4043 · DOI · Paper page
- Cork, 2015, Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain, Mol. Metab., 4, 718, 10.1016/j.molmet.2015.07.008 · DOI · Paper page
- Graham, 2013, GLP-1 analog attenuates cocaine reward, Mol. Psychiatry, 18, 961, 10.1038/mp.2012.141 · DOI · Paper page
- Graham, 2020, A novel mouse model of glucagon-like peptide-1 receptor expression: a look at the brain, J. Comp. Neurol., 528, 2445, 10.1002/cne.24905 · DOI · Paper page
- Monney, 2023, GLP-1 receptor agonists effect on cognitive function in patients with and without type 2 diabetes, Diabetes Metab., 49, 10.1016/j.diabet.2023.101470 · DOI · Paper page
- Nielsen, 2004, Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes, Regul. Pept., 117, 77, 10.1016/j.regpep.2003.10.028 · DOI · Paper page
- Tunstall, 2020, Chapter 26 - Rat Models of Alcohol Use Disorder, 967
- Vallöf, 2016, The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents, Addict. Biol., 21, 422, 10.1111/adb.12295 · DOI · Paper page
- Vallöf, 2020, Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats, Transl. Psychiatry, 10, 238, 10.1038/s41398-020-00923-1 · DOI · Paper page
- Liu, 2024, Liraglutide reduces alcohol consumption, anxiety, memory impairment, and synapse loss in alcohol dependent mice, Neurochem Res., 49, 1061, 10.1007/s11064-023-04093-6 · DOI
- Fink-Jensen, 2024, Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys, Psychopharmacology, 10.1007/s00213-024-06637-2 · DOI
- Thomsen, 2019, Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys, Psychopharmacol., 236, 603, 10.1007/s00213-018-5089-z · DOI · Paper page
- Marty, 2020, Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats, Front. Neurosci., 14, 10.3389/fnins.2020.599646 · DOI · Paper page
- Lan, 2012, Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways, Br. J. Pharm., 165, 2799, 10.1111/j.1476-5381.2011.01754.x · DOI · Paper page
- McKendrick, 2020, Drug-induced conditioned place preference and its practical use in substance use disorder research, Front. Behav. Neurosci., 14, 10.3389/fnbeh.2020.582147 · DOI · Paper page
- Shirazi, 2013, Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward, PLoS One, 8, 10.1371/journal.pone.0061965 · DOI · Paper page
- Díaz-Megido, 2023, Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL/6J mice, Psychopharmacol., 240, 1287, 10.1007/s00213-023-06367-x · DOI
- Sørensen, 2016, Effects of the GLP-1 agonist exendin-4 on intravenous ethanol self-administration in mice, Alcohol Clin. Exp. Res, 40, 2247, 10.1111/acer.13199 · DOI · Paper page
- Vallöf, 2019, Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents, Psychoneuroendocrinology, 103, 284, 10.1016/j.psyneuen.2019.02.006 · DOI · Paper page
- Vallöf, 2019, Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents, Neuropharmacology, 149, 124, 10.1016/j.neuropharm.2019.02.020 · DOI · Paper page
- Allingbjerg, 2023, Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice, Exp. Clin. Psychopharmacol., 31, 612, 10.1037/pha0000620 · DOI
- Abtahi, 2018, Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats, Neuroreport, 29, 1046, 10.1097/WNR.0000000000001071 · DOI · Paper page
- Colvin, 2020, Brain site-specific inhibitory effects of the GLP-1 analogue exendin-4 on alcohol intake and operant responding for palatable food, Int. J. Mol. Sci., 21, 10.3390/ijms21249710 · DOI · Paper page
- Colvin, 2022, Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats, Behav. Brain Res., 421, 10.1016/j.bbr.2021.113726 · DOI
- Dixon, 2020, Glucagon-like peptide-1 receptor signaling in the ventral tegmental area reduces alcohol self-administration in male rats, Alcohol Clin. Exp. Res., 44, 2118, 10.1111/acer.14437 · DOI · Paper page
- Lanng, 2019, Gluco-metabolic effects of oral and intravenous alcohol administration in men, Endocr. Connect, 8, 1372, 10.1530/EC-19-0317 · DOI
- Svartberg, 1998, The ethanol augmentation of glucose-induced insulin secretion is abolished by calcium antagonism with nifedipine: no evidence for a role of glucagon-like peptide-1 (GLP-1), Pancreas, 16, 66, 10.1097/00006676-199801000-00011 · DOI
- Arillotta, 2024, Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach, Brain Sci., 14, 10.3390/brainsci14060617 · DOI · Paper page
- Bremmer, 2024, Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders, J. Stud. Alcohol Drugs, 85, 5
- Quddos, 2023, Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity, Sci. Rep., 13, 10.1038/s41598-023-48267-2 · DOI · Paper page
- Wang, 2024, Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population, Nat. Commun., 15, 4548, 10.1038/s41467-024-48780-6 · DOI · Paper page
- Leggio, 2023, GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders, Nat. Med., 29, 2993, 10.1038/s41591-023-02634-8 · DOI · Paper page
- Hernandez, 2018, Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats, Neuropsychopharmacology, 43, 2000, 10.1038/s41386-018-0010-3 · DOI · Paper page
- Hernandez, 2019, Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats, Addict. Biol., 24, 170, 10.1111/adb.12583 · DOI · Paper page
- Hernandez, 2021, GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA, Mol. Psychiatry, 26, 4394, 10.1038/s41380-020-00957-3 · DOI · Paper page
- Harasta, 2015, Septal glucagon-like peptide 1 receptor expression determines suppression of cocaine-induced behavior, Neuropsychopharmacology, 40, 1969, 10.1038/npp.2015.47 · DOI
- Sørensen, 2015, The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice, Physiol. Behav., 149, 262, 10.1016/j.physbeh.2015.06.013 · DOI · Paper page
- Erreger, 2012, Exendin-4 decreases amphetamine-induced locomotor activity, Physiol. Behav., 106, 574, 10.1016/j.physbeh.2012.03.014 · DOI · Paper page
- Chaves Filho, 2020, The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: relevance for bipolar disorder, Prog. Neuropsychopharmacol. Biol. Psychiatry, 99, 10.1016/j.pnpbp.2020.109872 · DOI
- Fortin, 2017, Central GLP-1 receptor activation modulates cocaine-evoked phasic dopamine signaling in the nucleus accumbens core, Physiol. Behav., 176, 17, 10.1016/j.physbeh.2017.03.019 · DOI · Paper page
- Zhu, 2021, Glucagon-like peptide-1 agonist exendin-4 facilitates the extinction of cocaine-induced condition place preference, Front. Syst. Neurosci., 15, 10.3389/fnsys.2021.711750 · DOI
- Zhu, 2021, Glucagon-like peptide-1 analog exendin-4 ameliorates cocaine-mediated behavior by inhibiting toll-like receptor 4 signaling in mice, Front. Pharm., 12
- Zhu, 2021, Effects of glucagon-like peptide-1 receptor agonist exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice, Front. Behav. Neurosci., 15
- You, 2019, Cocaine and cocaine expectancy increase growth hormone, ghrelin, GLP-1, IGF-1, adiponectin, and corticosterone while decreasing leptin, insulin, GIP, and prolactin, Pharm. Biochem. Behav., 176, 53, 10.1016/j.pbb.2018.11.001 · DOI · Paper page
- Merkel, 2024, An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking, bioRxiv
- Bouhlal, 2017, Acute effects of intravenous cocaine administration on serum concentrations of ghrelin, amylin, glucagon-like peptide-1, insulin, leptin and peptide YY and relationships with cardiorespiratory and subjective responses, Drug Alcohol Depend., 180, 68, 10.1016/j.drugalcdep.2017.07.033 · DOI · Paper page
- Yammine, 2023, Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study, J. Addict. Med., 17, 481, 10.1097/ADM.0000000000001147 · DOI
- Douton, 2021, Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats, Behav. Pharm., 32, 265, 10.1097/FBP.0000000000000609 · DOI · Paper page
- Douton, 2022, Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-, stress-, and drug-induced heroin-seeking in rats, Behav. Pharm., 33, 364, 10.1097/FBP.0000000000000685 · DOI · Paper page
- Evans, 2022, Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats, Brain Res. Bull., 189, 163, 10.1016/j.brainresbull.2022.08.022 · DOI
- Zhang, 2021, A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats, Neuropharmacology, 192, 10.1016/j.neuropharm.2021.108599 · DOI
- Urbanik, 2022, Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats, Brain Res. Bull., 189, 155, 10.1016/j.brainresbull.2022.08.023 · DOI
- Łupina, 2020, The role of linagliptin, a selective dipeptidyl peptidase-4 inhibitor, in the morphine rewarding effects in rats, Neurochem Int., 133, 10.1016/j.neuint.2019.104616 · DOI
- Listos, 2022, Linagliptin, a selective dipeptidyl peptidase-4 inhibitor, reduces physical and behavioral effects of morphine withdrawal, Molecules, 27, 10.3390/molecules27082478 · DOI · Paper page
- Appenzeller, 2024, Obes. Drug cuts opiate craving
- Herman, 2023, Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats, Psychopharmacol., 240, 1373, 10.1007/s00213-023-06376-w · DOI
- Falk, 2023, GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity, Cell Rep., 42, 10.1016/j.celrep.2023.112466 · DOI
- Yammine, 2021, Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial, Nicotine Tob. Res., 23, 1682, 10.1093/ntr/ntab066 · DOI · Paper page
- Lengsfeld, 2023, Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial, EClinicalMedicine, 57, 10.1016/j.eclinm.2023.101865 · DOI · Paper page
- Farokhnia, 2020, Effects of oral, smoked, and vaporized cannabis on endocrine pathways related to appetite and metabolism: a randomized, double-blind, placebo-controlled, human laboratory study, Transl. Psychiatry, 10, 71, 10.1038/s41398-020-0756-3 · DOI
- Wang, 2024, Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study, Mol. Psychiatry, 10.1038/s41380-024-02498-5 · DOI · Paper page
- Doggrell, 2018, Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?, Expert Opin. Drug Metab. Toxicol., 14, 371, 10.1080/17425255.2018.1441286 · DOI
- Knudsen, 2016, Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus, J. Diabetes Invest., 7 Suppl 1, 56, 10.1111/jdi.12463 · DOI · Paper page
- Wise, 2008, Dopamine and reward: the anhedonia hypothesis 30 years on, Neurotox. Res., 14, 169, 10.1007/BF03033808 · DOI · Paper page
- Koob, 2023, Theoretical frameworks and mechanistic aspects of alcohol addiction: alcohol addiction as a reward deficit/stress surfeit disorder, Curr. Top. Behav. Neurosci., 10.1007/7854_2023_424 · DOI
- Mansur, 2017, Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: a pilot, open-label study, J. Affect. Disord., 207, 114, 10.1016/j.jad.2016.09.056 · DOI · Paper page
- Zhang, 2019, Olfactory dysfunction mediates adiposity in cognitive impairment of type 2 diabetes: insights from clinical and functional neuroimaging studies, Diabetes Care, 42, 1274, 10.2337/dc18-2584 · DOI
- Watson, 2019, Neural correlates of liraglutide effects in persons at risk for Alzheimer’s disease, Behav. Brain Res., 356, 271, 10.1016/j.bbr.2018.08.006 · DOI · Paper page
- Kopp, 2024, Type 2 diabetes mellitus/obesity drugs: a neurodegenerative disorders savior or a bridge too far?, Ageing Res. Rev., 98, 10.1016/j.arr.2024.102343 · DOI
- Ghidewon, 2022, Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms, Diabetes Obes. Metab., 24, 1010
- Kinzig, 2002, The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness, J. Neurosci., 22, 10470, 10.1523/JNEUROSCI.22-23-10470.2002 · DOI · Paper page
- Thiele, 1997, Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats, Am. J. Physiol. Regul. Integr. Comp. Physiol., 272, R726, 10.1152/ajpregu.1997.272.2.R726 · DOI · Paper page
- Seeley, 2000, The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride, J. Neurosci., 20, 1616, 10.1523/JNEUROSCI.20-04-01616.2000 · DOI · Paper page
- Heilig, 2021, Addiction as a brain disease revised: why it still matters, and the need for consilience, Neuropsychopharmacology, 46, 1715, 10.1038/s41386-020-00950-y · doi:10.1038/s41386-020-00950-y
- Ørskov, 1996, Glucagon-like peptide i receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I, Diabetes, 45, 832, 10.2337/diab.45.6.832 · DOI · Paper page
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
O'Keefe, J. H., Franco, W. G., & O'Keefe, E. L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.12.010 · Cited by 42
Srivastava, G., Campbell, S. L., Hill, C. R., Stanley, T. L., Lawson, E. A., Apovian, C. M., Almandoz, J. P., Leggio, L., Lakdawalla, D. N., Dar, M., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.06.015 · Cited by 5
“For a recent comprehensive review focused on the emerging literature on the role of GLP-1RAs in AUD and SUD, see Bruns et al. [105].”
Self-citation
Metadata
- Authors
- Bruns VI, N., Tressler, E. H., Vendruscolo, L. F., Leggio, L., & Farokhnia, M.
- Venue
- Pharmacological Research
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 207
- Pages
- 107312
- ISSN
- 1043-6618 (ISSN-L)
- OpenAlex
- W4400766615
- Cited by
- 89
- References
- 48
- FWCI
- 23.27
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- National Institutes of Health
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.